Aberrant Activation of the Hedgehog Signaling Pathway in Malignant Hematological Neoplasms
November 2011
in “
The American journal of pathology
”
TLDR Abnormal Hedgehog signaling in blood cancers may help tumors grow and resist chemotherapy, suggesting potential for targeted treatments.
The document discussed the aberrant activation of the Hedgehog (HH) signaling pathway in various malignant hematological neoplasms, including chronic lymphocytic leukemia, plasma cell myeloma, and diffuse large B-cell lymphoma. It highlighted that HH signaling, crucial for normal cell differentiation and survival, could be abnormally activated in cancers, contributing to tumor maintenance, growth, and chemotherapy resistance. The study emphasized the potential therapeutic value of HH pathway inhibitors to enhance the effectiveness of existing chemotherapies and suggested further research to understand the mechanisms behind HH pathway activation and its interaction with other oncogenic pathways.
